CC
Caitlin Conboy
Also known as: CM Conboy, CB Conboy
Mayo Clinic
Research areas: Medicine · Surgery · Cholangiocarcinoma and Gallbladder Cancer Studies · Hippo pathway signaling and YAP/TAZ · Protein Tyrosine Phosphatases
0000-0001-8280-056X
Employment
- 2023 - Present
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (30)
- The Effect of Neoadjuvant Therapy on Post-Recurrence Overall Survival After Curative Resection for Intrahepatic Cholangiocarcinoma Save
- Multiomics combined with machine learning defines unique molecular subtypes of cholangiocarcinoma and identifies TNK1 as a therapeutic target Save
- Neoadjuvant Therapy as a Selection Strategy for Curative Resection in High-Risk Intrahepatic Cholangiocarcinoma Save
- Real-world outcomes of adjuvant therapy after curative-intent resection for biliary tract cancer Save
- Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers Save
- Perioperative and oncologic outcomes of vascular resection after neoadjuvant therapy in intrahepatic cholangiocarcinoma Save
- Multiomics-driven discovery of predictive biomarkers and strategies to overcome resistance to SFK-YAP inhibition in cholangiocarcinoma Save
- The oncogenic potential of YAP requires Y357 phosphorylation in cholangiocytes but not in hepatocytes Save
- First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study Save
- Conversion to Resection After Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Borderline Resectable CCA: A Real-World Exploratory Analysis Save
- Real-World Single-Center Experience with Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab in Borderline Resectable Cholangiocarcinoma Save
- A Phase 1 study of the novel GCN2 kinase activator NXP800 in patients with advanced cholangiocarcinoma Save
- YAP‐TEAD inhibition is associated with upregulation of an androgen receptor mediated transcription program providing therapeutic escape Save
- Data from The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma Save
- LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma Save
- Drivers and breaks in the cholangiocarcinoma immune microenvironment. Save
- R-Spondins 2 and 3 Are Overexpressed in a Subset of Human Colon and Breast Cancers. Save
- The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma Save
- Targeting tumor-associated macrophages and granulocytic-myeloid-derived suppressor cells augments pd-1 blockade in cholangiocarcinoma Save
- R-spondin 2 Drives Liver Tumor Development in a Yes-Associated Protein-Dependent Manner. Save